Overview

Detailed Summary

Pfizer Limited is a major pharmaceutical company involved in the manufacture, marketing, and export of a range of pharmaceutical products, including specialized medicines across 15 therapeutic areas. It operates manufacturing facilities in Goa and Thane, contributing to its extensive global footprint with 43 facilities worldwide.
The company has a rich history in India dating back to 1950, being the first to introduce clinical research in the country. It has evolved through strategic mergers and collaboration, most recently merging with Wyeth Limited and divesting several older product lines.
Recent product launches include Betrecep for treatment of Rheumatoid Arthritis and other conditions, showcasing Pfizer's commitment to innovation in therapeutic solutions.
Pfizer Limited significantly altered its operational scope through divestitures to Mylan, impacting its branded and generic established medicines portfolio, a move indicating strategic refocus.
They continue to bolster their respiratory portfolio with various line extensions under the Corex brand, even as it phases out older formulations in response to regulatory challenges.

Sector: Pharmaceuticals
Industry: Pharmaceuticals - Multinational
Market Cap: 23,031 Cr
Volatility: Low Risk
P/E Ratio: 30.2
Industry P/E: 39.5
PEG Ratio: 5.4
P/B Ratio: 6.0
52W High: 5,987.65
52W Low: 3,742.90

Sales CAGR

1Y: -0.43%
3Y: -4.40%
5Y: 1.18%
10Y: 0.93%

Profit CAGR

1Y: -11.89%
3Y: 7.81%
5Y: 8.56%
10Y: 14.74%

ROE

TTM: 18.36%
3Y: 17.63%
5Y: 18.76%
10Y: 16.42%

ROCE

TTM: 24.12%
3Y: 23.08%
5Y: 24.20%
10Y: 22.28%

Technicals

‌

Forecasts

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
ABBOTINDIA	26518.70	56,249 Cr	37.35	14.02	1.79	37.62	48.38	26.77
GLAXO	2590.00	43,942 Cr	43.62	25.73	2.08	55.94	74.64	27.86
PFIZER	5033.50	23,031 Cr	30.24	5.98	3.28	18.36	24.12	18.53
ASTRAZEN	8810.00	22,197 Cr	105.88	27.78	0.36	28.93	37.48	12.44
SANOFICONR	4277.30	9,902 Cr	45.84	38.53	1.28	77.82	92.58	51.64
SANOFI	4031.60	9,312 Cr	24.44	10.82	2.89	42.11	52.41	25.64
PGHL	4975.55	8,259 Cr	28.14	13.33	2.51	49.51	65.17	32.81

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Standalone Quarterly Results (in ₹ Crores)

Total Figures

QoQ Changes

Total Figures

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	575	540	547	563	589	538	592	603	642	645
Expenses	393	387	357	385	399	392	364	393	412	417
Operating Profit	183	153	189	177	189	146	227	210	230	228
OPM %	31.75	28.25	34.65	31.53	32.15	27.14	38.43	34.83	35.80	35.38
Other Income	36	44	75	42	43	43	217	67	42	-20
Interest	2.73	2.86	6.95	2.11	2.10	1.51	2.69	3.25	2.13	1.99
Depreciation	15	18	14	15	15	15	16	14	14	14
Profit Before Tax	201	176	244	203	215	172	426	260	255	192
Tax %	25.71	26.12	26.65	25.62	26.43	26.00	22.28	26.12	25.98	26.11
Net Profit	149	130	179	151	158	128	331	192	189	142
EPS in Rs	32.56	28.42	39.09	32.94	34.61	27.89	72.34	41.91	41.32	31.01

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	2,042	1,980	2,082	2,152	2,239	2,611	2,425	2,193	2,281	2,322
Expenses	1,617	1,468	1,516	1,579	1,526	1,775	1,616	1,558	1,541	1,549
Operating Profit	425	512	565	573	712	836	809	635	740	773
OPM %	20.80	25.85	27.15	26.61	31.81	32.01	33.36	28.97	32.45	33.29
Other Income	232	114	167	184	81	63	134	188	345	370
Interest	0.96	0.42	1.29	11	15	10	13	15	8.41	9.55
Depreciation	63	66	71	103	109	115	106	62	61	61
Profit Before Tax	517	548	660	642	669	773	824	746	1,016	1,073
Tax %	34.84	34.28	34.98	20.76	25.59	20.74	24.28	26.10	24.46	24.64
Net Profit	337	360	429	509	498	613	624	551	768	809
EPS in Rs	73.61	78.70	93.78	111.30	108.76	133.90	138.06	120.51	167.78	186.58
Dividend Payout %	27.17	25.41	23.99	296.55	32.18	26.14	51.33	29.04	98.34	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	46	46	46	46	46	46	46	46	46	46
Reserves	2,072	2,373	2,637	2,966	3,350	2,347	2,819	3,162	3,550	4,172
Borrowings	2.50	2.50	2.50	2.50	2.50	2.50	39	41	40	41
Other Liabilities	793	840	1,004	926	1,007	870	997	752	593	653
Total Liabilities	2,914	3,261	3,690	3,940	4,405	3,266	3,901	4,001	4,229	4,911
Fixed Assets	859	867	917	854	942	865	841	749	713	724
CWIP	3.27	15	1.04	0.00	0.76	2.76	1.15	7.93	0.40	7.64
Investments	41	35	34	32	31	30	28	0.00	0.00	0.00
Other Assets	2,011	2,343	2,739	3,054	3,432	2,369	3,030	3,244	3,516	4,180
Total Assets	2,914	3,261	3,690	3,940	4,405	3,266	3,901	4,001	4,229	4,911

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	344	329	332	98	323	427	667	356	257	660
Cash from Investing Activity	-699	-250	-238	35	1,530	-469	-575	-36	54	-71
Cash from Financing Activity	-62	-83	-110	-110	-164	-1,571	-181	-346	-235	-205
Net Cash Flow	-417	-3.41	-17	23	1,690	-1,613	-88	-26	75	383

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	63.92%	63.92%	63.92%	63.92%	63.92%	63.92%	63.92%	63.92%	63.92%	63.92%	63.92%	63.92%
FIIs	2.80%	2.81%	2.82%	3.03%	3.32%	3.22%	3.54%	2.75%	2.18%	2.39%	2.60%	2.71%
DIIs	14.90%	14.89%	15.01%	15.15%	15.33%	15.84%	16.04%	16.79%	17.10%	17.23%	17.10%	17.05%
Public	18.38%	18.37%	18.25%	17.90%	17.42%	17.01%	16.50%	16.54%	16.79%	16.45%	16.37%	16.32%
Total Shareholders	1,17,194	1,15,988	1,16,948	1,12,456	1,09,214	1,06,098	98,824	1,05,015	1,08,261	1,03,222	1,03,480	1,00,933

Market Transactions

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Projection

Unlock Premium Features

Get In-depth insights on EPS and Revenue forecasts

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Financial Results

6 days ago

Pfizer Limited's Unaudited Financial Results

Pfizer Limited announces the board's approval of its unaudited financial results for the quarter and nine months ended December 31, 2025, during a meeting held on February 9, 2026.

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Pfizer Ltd

Pfizer Ltd (PFIZER) is currently trading at 5,033.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Pfizer Limited is a major pharmaceutical company involved in the manufacture, marketing, and export of a range of pharmaceutical products, including specialized medicines across 15 therapeutic areas. It operates manufacturing facilities in Goa and Thane, contributing to its extensive global footprint with 43 facilities worldwide. The company has a rich history in India dating back to 1950, being the first to introduce clinical research in the country. It has evolved through strategic mergers and collaboration, most recently merging with Wyeth Limited and divesting several older product lines. Recent product launches include Betrecep for treatment of Rheumatoid Arthritis and other conditions, showcasing Pfizer's commitment to innovation in therapeutic solutions. Pfizer Limited significantly altered its operational scope through divestitures to Mylan, impacting its branded and generic established medicines portfolio, a move indicating strategic refocus. They continue to bolster their respiratory portfolio with various line extensions under the Corex brand, even as it phases out older formulations in response to regulatory challenges.

Over the past 52 weeks, Pfizer Ltd has traded between a low of ₹3,742.90 and a high of ₹5,987.65. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Pfizer Ltd has a market capitalization of approximately 23,031.47. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Pfizer Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 30.24 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 23,031.47 Cr, Pfizer Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Pfizer Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Pfizer Ltd is 30.24. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Pfizer India's stock surged over 10% due to its strong Q3 FY26 financial results, which included a 19.9% year-on-year revenue growth to ₹645.03 crore and a significant expansion of operating margins to 35.4%.

Pfizer reported an 11.1% year-on-year increase in net profit to ₹141.84 crore and a 19.9% rise in revenue to ₹645 crore. EBITDA surged by 55.8%, and operating margins expanded significantly to 35.4%.

For the second quarter of fiscal year 2026, Pfizer India reported a net profit of ₹189.02 crore, which represents a 19.4% increase year-on-year.

The Union Budget 2026's exemption of basic customs duty on 17 drugs and 7 rare disease treatments can reduce Pfizer Ltd.'s import costs for relevant products, potentially improving profit margins and making medicines more affordable.

Pfizer Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Unlock Premium Features

Upgrade

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

Ask AI

Standalone Quarterly Results (in ₹ Crores)

Standalone Profit Loss (in ₹ Crores)

Standalone Balance Sheet (in ₹ Crores)

Standalone Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Unlock Premium Features

Upgrade

Projection

Unlock Premium Features

Upgrade

Documents

Actions

Announcements

Pfizer Limited's Unaudited Financial Results

AI Mode

Ask AI

Frequently Asked Questions about Pfizer Ltd

What is Pfizer Ltd share price today?

What does Pfizer Ltd do?

What is the 52-week high and low of Pfizer Ltd?

What is the market capitalization of Pfizer Ltd?

Should I consider investing in Pfizer Ltd stock?

Is Pfizer Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Pfizer Ltd belong to and why does it matter?

What is the PE ratio of Pfizer Ltd?

Why did Pfizer India's stock price increase by over 10% in February 2026?

What were the key highlights of Pfizer's Q3 FY26 results?

What was Pfizer India's net profit in Q2 FY26?

How does Union Budget 2026 impact Pfizer Ltd.'s profitability?

Utility

Company

Technicals

Overview

Financial Ratios

Forecasts

Unlock Premium Features

Upgrade

Frequently Asked Questions about Pfizer Ltd

What is Pfizer Ltd share price today?

What does Pfizer Ltd do?

What is the 52-week high and low of Pfizer Ltd?

What is the market capitalization of Pfizer Ltd?

Should I consider investing in Pfizer Ltd stock?

Is Pfizer Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Pfizer Ltd belong to and why does it matter?

What is the PE ratio of Pfizer Ltd?

Why did Pfizer India's stock price increase by over 10% in February 2026?

What were the key highlights of Pfizer's Q3 FY26 results?

What was Pfizer India's net profit in Q2 FY26?

How does Union Budget 2026 impact Pfizer Ltd.'s profitability?

Documents

Oscillators

Bearish

Overall

Bullish

Moving Averages

Bullish

Overall

Bullish

Financial Statements

AI Powered Summary

Ask AI

Standalone Quarterly Results (in ₹ Crores)